Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's performance in the first half of 2025 met expectations, driven by both domestic and international markets [2][10] - The company is expected to see a rapid recovery in its home respiratory machine business as channel inventory clears, alongside high growth in consumables [3] - The target price is set at 121.44 CNY, based on a 46 times price-to-earnings ratio for 2025 [3] Financial Performance Summary - For 2023, the company reported a revenue of 1,122 million CNY, with a year-on-year decline of 20.7%. The forecast for 2025 is 1,072 million CNY, reflecting a growth of 27.1% [4] - The net profit attributable to the parent company for 2023 was 297 million CNY, down 21.8% year-on-year, with a projected increase to 237 million CNY in 2025, representing a growth of 52.4% [4] - The earnings per share (EPS) for 2025 is estimated at 2.64 CNY, with subsequent years projected at 3.35 CNY for 2026 and 4.11 CNY for 2027 [3][4] Business Segment Insights - In the first half of 2025, the company achieved a revenue of 540 million CNY, a year-on-year increase of 42.3%, with the home respiratory machine segment contributing 350 million CNY, up 51.5% [9] - The domestic business saw a revenue of 190 million CNY in the first half of 2025, growing by 16.9% due to comprehensive channel reforms and sales policy adjustments [9] - The international business generated 350 million CNY in revenue, marking a 61.3% increase, with significant contributions from the U.S. market [9]
瑞迈特（301367）：业绩符合预期，国内外双轮驱动